DXCM (DexCom) Research & Development: $604 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DXCM DexCom Inc DXCM
94 GF Score
Price $84.75
GF Value $101.15
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is DexCom Research & Development?

DexCom DXCM +2.08% 94 Research & Development is $604 Mil as of Jun. 2026. GuruFocus rates DXCM with a GF Score™ of 94/100 and a GF Value™ of $101.15 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. DexCom's Research & Development for the three months ended in Jun. 2026 was $153 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was $604 Mil.

DexCom  (NAS:DXCM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

DexCom Research & Development Related Terms

DexCom Research & Development Historical Data

* Premium members only.

The historical data trend for DexCom's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Research & Development Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 604.20 484.20 505.80 552.40 599.10

DexCom Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 148.20 157.50 148.20 145.30 153.00
DXCM
94GF Score
DexCom Inc DXCM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $604 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $604 Mil mean?
DexCom (DXCM) has a Research & Development of $604 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on DexCom and its competitors.
Is DexCom's Research & Development too high?
DexCom's current Research & Development is $604 Mil. Overall, DexCom has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Research & Development compare to GEHC and STE?
DexCom's Research & Development of $604 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on DexCom and its competitors. DexCom's current Research & Development is $604 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.15, compared to a current price of $84.75 — trading 16.2% below its estimated fair value. The current Research & Development is $604 Mil. DexCom's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For DexCom (DXCM), the current Research & Development is $604 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of $84.75 is trading 16.2% below its estimated GF Value™ of $101.15. GuruFocus considers DexCom to be Modestly Undervalued.

Key valuation signals for DXCM:

  • Research & Development: $604 Mil
  • GF Value™: $101.15 vs. price of $84.75 (16.2% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
94GF Score

Get the complete analysis for DXCM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$84.75
Price
$101.15
GF Value